文献速递肾小球疾病

KDIGO评述:补体抑制剂与B细胞修饰药物治疗IgA肾病

Complement inhibitors and B cell-modifying agents for IgA nephropathy-a Kidney Disease: Improving Global Outcomes (KDIGO) commentary.
PubMed 文献 · Kidney Int · 2026-03-26

KDIGO在2021年更新肾小球疾病指南后,IgA肾病治疗进展迅速,2025年再次更新IgA肾病指南。此后又有3种IgA肾病疗法获美国FDA加速批准,其中2种作用机制与既往药物不同。KDIGO IgA肾病工作组因此发表简要评述,阐述这些新疗法在整体治疗策略中的可能定位。

要点

  • 2025年KDIGO更新IgA肾病指南后,又有3种疗法获FDA加速批准。
  • 其中2种新疗法作用机制与既往获批药物不同。
  • 评述旨在说明新疗法在IgA肾病治疗策略中的定位。

核心结论

  • KDIGO IgA肾病工作组发表评述,阐述补体抑制剂和B细胞修饰药物等新疗法在IgA肾病整体治疗策略中的可能定位。

研究设计与样本

  • KDIGO IgA肾病工作组针对2025年指南更新后新获批疗法撰写的简要评述,非系统综述或指南更新。

主要发现

  • 2025年IgA肾病指南更新后,有3种额外IgA肾病治疗获美国FDA加速批准。
  • 其中2种新疗法的推定作用机制与既往获批药物不同。

临床怎么用

  • 在等待更多证据期间,可参考该评述理解补体抑制剂和B细胞修饰药物在IgA肾病治疗策略中的可能位置。

局限性

  • 该文为简要评述而非完整指南更新,新疗法的定位有待额外证据支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Kidney Disease: Improving Global Outcomes (KDIGO) updated its clinical practice guideline for the management of glomerular diseases in 2021, more than a decade after the first glomerular diseases guideline was published, reflecting slow progress in drug development. But since then, novel therapies for several glomerular diseases have been successfully tested and approved by regulatory agencies, none more so than IgA nephropathy (IgAN). To keep pace with new therapies, the IgAN guideline was updated again in 2025. After this revision came to press, 3 additional IgAN treatments received accelerated approval by the US Food and Drug Administration. Because the presumptive mechanisms of action of 2 of these new therapies are mechanistically different from those of previously approved drugs, the KDIGO IgAN Work Group felt that a brief commentary outlining where the new therapies may fit into the overall IgAN treatment strategy was warranted in lieu of a full guideline update, pending additional evidence for these and other therapies.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Rovin BH, Barratt J, Cook HT, et al. Complement inhibitors and B cell-modifying agents for IgA nephropathy-a Kidney Disease: Improving Global Outcomes (KDIGO) commentary. Kidney Int. 2026. PMID: 41895685. doi:10.1016/j.kint.2026.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。